• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Simcere Pharmaceutical Group - Product Pipeline Review - Q4 2010 - Product Image

Simcere Pharmaceutical Group - Product Pipeline Review - Q4 2010

  • ID: 1446999
  • November 2010
  • 64 pages
  • Global Markets Direct

Simcere Pharmaceutical Group – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Simcere Pharmaceutical Group - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Simcere Pharmaceutical Group - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Simcere Pharmaceutical Group human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
Simcere Pharmaceutical Group Snapshot
Simcere Pharmaceutical Group Overview
Key Information
Key Facts
Simcere Pharmaceutical Group – Research and Development Overview
Key Therapeutic Areas
Simcere Pharmaceutical Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Simcere Pharmaceutical Group – Pipeline Products Glance
Simcere Pharmaceutical Group – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Simcere Pharmaceutical Group Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Simcere Pharmaceutical Group–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Simcere Pharmaceutical Group – Drug Profiles
Iguratimod
Product Description
Mechanism of Action
R&D Progress
Dacarbazine + Endostar
Product Description
Mechanism of Action
R&D Progress
Endu + Etoposide + Carboplatin
Product Description
Mechanism of Action
R&D Progress
FOLFOX4 + Endostar
Product Description
Mechanism of Action
R&D Progress
Levamisole Hydrochloride Nasal Spray
Product Description
Mechanism of Action
R&D Progress
Rh-RGD-Hirudin
Product Description
Mechanism of Action
R&D Progress
Bendamustine
Product Description
Mechanism of Action
R&D Progress
Triflusal
Product Description
Mechanism of Action
R&D Progress
BMS-817378
Product Description
Mechanism of Action
R&D Progress
SIM010603
Product Description
Mechanism of Action
R&D Progress
SIM6802
Product Description
Mechanism of Action
R&D Progress
Epitomics Anti-body
Product Description
Mechanism of Action
R&D Progress
SIM0702
Product Description
Mechanism of Action
R&D Progress
SIM0710
Product Description
Mechanism of Action
R&D Progress
SIM071201
Product Description
Mechanism of Action
R&D Progress
Simcere Pharmaceutical Group – Pipeline Analysis
Simcere Pharmaceutical Group – Pipeline Products by Therapeutic Class
Simcere Pharmaceutical Group Pipeline Products By Target
Simcere Pharmaceutical Group – Pipeline Products by Route of Administration
Simcere Pharmaceutical Group – Pipeline Products by Molecule Type
Simcere Pharmaceutical Group – Recent Pipeline Updates
Simcere Pharmaceutical Group – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Aug 12, 2010: Simcere Receives SFDA Approval To Manufacture And Market Palonosetron In China
Mar 22, 2010: Simcere Completes Endostar Phase IV Clinical Study
Mar 22, 2010: Simcere Completes Endostar Phase IV Clinical Study
Feb 11, 2010: Simcere Receives SFDA Approval For Zanamivir In China
Financial Deals Landscape
Simcere Pharmaceutical Group, Deals Volume Summary, 2004 to YTD 2010
Simcere Pharmaceutical Group, Deals Summary By Region, 2004 to YTD 2010
Simcere Pharmaceutical Group, Deals Summary, 2004 to YTD 2010
Simcere Pharmaceutical Group Detailed Deal Summary
Asset Purchase
Trinity Health Acquires Three Hospitals From Catholic Health Initiatives
Acquisition
Simcere Pharmaceutical Increases Its Stake In Jiangsu Yanshen Biological Technology Stock
Simcere Pharmaceutical Acquires 35.1% Stake In Shanghai Celgen Bio-Pharmaceutical
Simcere Pharmaceutical Acquires 37.5% Stake in Jiangsu Yanshen Biological
Simcere Pharmaceutical To Acquire Stake In Tianjin Tianda Pharmaceutical
Equity Offering
Simcere Pharmaceutical Completes Initial Public Offering Of $181 Million
Debt Offering
Trinity Health Completes Private Placement Of Variable Rate Bonds For $793 Million
Trinity Health Completes Private Placement Of Bonds For $492 Million
Simcere Pharmaceutical Enters Into Co-Development And Marketing Agreement With OSI Pharmaceuticals
Simcere Pharmaceutical Enters Into Agreement With Sun Yat-Sen University
Licensing Agreements
GlaxoSmithKline Signs A Licensing Agreement With Simcere Pharmaceutical
GlaxoSmithKline Enters Into Licensing Agreement With Simcere Pharmaceutical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS